Despite being at low bleeding risk, gastrointestinal (GI) mucosal injury was detected in most patients undergoing percutaneous coronary intervention (PCI), with continuation of dual antiplatelet therapy (DAPT) resulting in a higher risk of GI injury and bleeding, according to new trial data.